18:09 , Jun 1, 2018 |  BC Week In Review  |  Financial News

JHL raises $106M in bond deal

Biosimilars company JHL Biotech Inc. (Zhubei, Taiwan) raised $106 million on May 15 in convertible bonds led by new investor VMS Investment Group, according to JHL CFO Ellis Chu. Also participating were new investor Ruihua...
16:45 , May 30, 2018 |  BC Extra  |  Financial News

JHL raises $106M in bond deal

Biosimilars company JHL Biotech Inc. (Zhubei, Taiwan) raised $106 million in convertible bonds led by new investor VMS Investment Group, according to JHL CFO Ellis Chu. Also participating were Ruihua Investment, existing investor Milestone Capital...
19:36 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

EC approves Amgen's biosimilar Avastin

Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) said the European Commission approved Mvasi (ABP 215), a biosimilar of Avastin bevacizumab. The approval includes all cancer types on Avastin's EU label -- non-small cell lung cancer...
03:33 , Nov 17, 2017 |  BC Week In Review  |  Clinical News

CHMP recommends Amgen's Avastin biosimilar ABP 215

EMA's CHMP recommended approval of ABP 215 from Amgen Inc. (NASDAQ:AMGN), a biosimilar of Avastin bevacizumab, for all cancer types on Avastin's EU label: non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and colorectal,...
23:46 , Sep 19, 2017 |  BC Extra  |  Company News

Management tracks: OncoMed, Vividion, Spero

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman and CEO Paul Hastings began a medical leave of absence. Proteomics company Vividion Therapeutics Inc. (San Diego, Calif.) named Diego Miralles CEO. He was president of the...
21:09 , Sep 15, 2017 |  BC Week In Review  |  Clinical News

FDA approves first biosimilar for cancer

FDA approved a BLA from Amgen Inc. (NASDAQ:AMGN) for Mvasi bevacizumab-awwb (ABP 215), a biosimilar of cancer drug Avastin bevacizumab. FDA said Mvasi is the first biosimilar approved in the U.S. to treat cancer. Mvasi...
19:31 , Jul 14, 2017 |  BC Week In Review  |  Clinical News

FDA panel backs approval of Amgen's Avastin biosimilar

FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 17-0 in favor of approving ABP 215 from Amgen Inc. (NASDAQ:AMGN). The product is a biosimilar of Avastin bevacizumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHBBY)....
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
20:19 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

FDA panel to discuss Avastin biosimilar from Amgen, Allergan

FDA’s Oncologic Drugs Advisory Committee (ODAC) will meet on July 13 to discuss a BLA for biosimilar ABP 215. Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) share rights to ABP 215, a proposed biosimilar for...
17:20 , Dec 16, 2016 |  BC Week In Review  |  Company News

JHL, Sanofi deal

JHL granted Sanofi exclusive, Chinese development and commercialization rights to biosimilar rituximab (JHL1101). JHL will receive $21 million up front and is eligible for up to $236 million in milestones, plus royalties. Sanofi also invested...